
Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies

Chan Y. Cheah MBBS, DMSc¹, Wojciech Jurczak MD², Masa Lasica MBBS⁴, Tomasz Wróbel MD⁵, Jan Walewski MD⁶, Costas K. Yannakou MBBS (Hons)⁷, Stanley Cheung MBBS⁴, Katharine L. Lewis MBBS¹, Monika Długosz-Danecka MD, PhD², Krzysztof Giannopoulos MD⁸, Hari P. Miskin MS⁹, Emmanuel Normant PhD⁹, Owen A. O'Connor, MD, PhD⁹, Alejandro D. Ricart MD⁹, Constantine S. Tam MBBS (Hons), MD³ ¹Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia; ²Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; ³St. Vincent Hospital and University of Melbourne, Melbourne, Victoria; 4 Ashford Cancer Centre Research, Adelaide, South Australia; 5 Wroclaw Medical University, Poland; 7 Department of Molecular Oncology and Cancer Immunology, Epworth HealthCare, East Melbourne, Victoria; ⁸Hematology Department, St John's Cancer Centre, Lublin, Poland; ⁹TG Therapeutics, Inc., New York, NY.



	Dose-escalation Phase		Disease-specific Cohorts			
	TG-1701	TG-1701 + U2 (N = 19)	200 mg QD			300 mg QD
Characteristic	(N = 25)		CLL (N = 20)	WM (N = 20)	MCL (N = 21)	CLL (N = 20)
Male sex N(%)	14 (56)	8 (42)	7 (35)	12 (60)	13 (62)	10 (50)
Age, years, median (min/max) ≥75 years N(%)	68 (49 / 86) <i>7 (28)</i>	69 (47/81) <i>5 (26)</i>	71 (53 /87) <i>4 (20)</i>	73 (57/92) <i>8(40)</i>	70 (57 /85) <i>5(24)</i>	71 (49/ 78) <i>6(30)</i>
ECOG 0 / 1 / 2 (%)	56 / 44 / 0	79/21/0	35/65/0	45 / 50 / 5	48/48/4	35/65/0
Prior therapies, median (range)	1(1-5)	2 (1 - 5)	1(0-5)	1(0-4)	3 (0 – 10)	1(0-5)
Refractory to last prior therapy N(%)	7 (28)	3 (16)	2 (10)	3 (15)	4 (19)	1(5)
Prev. anti-CD20 therapy N(%)	25 (100)	19 (100)	14 (93)*	12 (100)*	18 (100)*	14 (93)*
Treatment-naïve N(%)	-	-	5 (25)	8 (40)	3 (14)	4 (20)

*Calculation excludes treatment-naïve patients

	Patient Dis	position				
	Dose-escala	tion Phase	Disease-specific Cohorts			
off: Apr 30, 2021	TG-1701 (N=25)	TG-1701 + U2 (N=19)	200 mg (N=61)	300 mg (N=20)		
oing treatment N(%)	18 (72)	16 (84)	45 (74)	18 (90)		
a-pt dose escalation N(%)	7 (28)	-	-	-		
e redn. (any agent) N(%)	4 (16)	5 (31)	2 (3)	1(5)		
off study N(%)	7 (28)	3 (16)	16 (26)	2 (10)		
son for tx d/c N(%)						
Progression by criteria	5 (20)	2 (11)	10 (16)	-		
Clinical progression	-	-	1(2)	-		
Treatment-related AE	-	-	1(2)	-		
Non-treatment related AE	-	1(5)	2 (3)	2 (10)		
Pt / physician decision - Other	2 (8)	-	2 (3)	-		

Safety

All Causality AEs (≥10%) TG-1701 Monotherapy						
dverse event, N (%)	Dose escalation (100 to 400 mg) N=25		Disease-specific cohorts (200 mg) N=61		CLL cohort (300 mg) N=20	
	Any Grade	Grade 3	Any Grade	Grade ≥3	Any Grade	Grade ≥3
espiratory tract fection	9 (36)	2 (8)	6 (10)	-	2 (10)	-
onstipation	8 (32)	-	3 (5)	-	-	-
ruising	7 (28)	-	5 (8)	-	-	-
ntigue	5 (20)	-	2 (3)	-	1(5)	-
ash	4 (20)	1(4)	3 (5)	-	1(5)	-
ausea	4 (16)	-	1(2)	-	2 (10)	-
zziness	4 (16)	-	1(2)	-	-	-
eadache	3 (12)	-	6 (10)	-	1(5)	-
arrhea	3 (12)	-	7 (11)	-	2 (10)	-
oistaxis	3 (12)	-	2 (3)	-	-	-
DVID-19	-	-	4 (7)	1(2)	3 (15)	2 (10)
ematologic and lab phormalities	Any Grade	Grade 3	Any Grade	Grade ≥3	Any Grade	Grade ≥3
eutropenia	6 (24)	2 (8)	8 (13)	5 (8)	2 (10)	2 (10)
_T increased	6 (24)	3 (12) a	5 (8)	1(2)	3 (15)	1(5)
ST increased	5 (20)	1(4)	3 (5)	-	3 (15)	1(5)
nemia	4 (16)	-	7 (11)	3 (5)	-	-
		_		_		


• There have been no G4 AEs in the dose escalation of monotherapy • At 200mg and 300 mg QD (n=81), AE's of special interest were G3 hypertension 4.9% and atrial fibrillation 1.2%. There have been no instances of major bleeding ^aAll at 400 mg QD. 2 cases were brief episodes in asymptomatic pts with normal liver function (total bilirubin within normal range).

1 case was in the context of significant progression of disease in the liver.

All Causality AEs (≥15%) TG-1701+U2 Combo						
	Patients (N = 19)					
dverse event, N(%)	Any Grade	Grade 3	Grade 4			
arrhea	9 (47)	2 (11)	-			
Rª	9 (47)	1(5)	_			
uising	9 (47)	-	-			
ausea	6 (32)	1(5)	-			
/pertension	6 (32)	1(5)	-			
itigue	4 (21)	-	-			
ash	3 (16)	-	-			
omiting	3 (16)	-	-			
ematologic and laboratory phormalities	Any Grade	Grade 3	Grade 4			
eutropenia	7 (37)	2 (11)	2 (11)			
T increased	6 (32)	3 (16) ^b	1(5) ^c			
ST increased	6 (32)	3 (16)	-			

^bAll cases of G₃ ALT increased were in patients with normal liver function (total bilirubin within normal range). Two patients continue therapy at a reduced dose of umbralisib (600 mg and 400 mg). The third patient discontinued ublituximab due to serum sickness.


^cThe G4 ALT increased was symptomatic (vomiting) and with abnormal liver function, the patient has recovered with complete response and remains on study therapy.





The combination of TG-1701 with U2 has been well tolerated and dose escalation continues. Combination treatment is associated with encouraging clinical activity, including early complete responses

Presented at the International Conference on Malignant Lymphoma Lugano Virtual Meeting June 18-22, 2021.



SUMMARY

TG-1701 exhibits an encouraging safety profile, with clinical and pharmacodynamic activity at all dose levels evaluated that support QD dosing The MTD has not been achieved in the monotherapy arm (up to 400mg QD)

• This study (NCT03671590) continues enrollment and future registration trials are being planned

Acknowledgements

Thank you to the patients and their families for their participation.

